Avadel Pharmaceuticals
Quarterly Financials
| Values in thousands | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 |
|---|---|---|---|---|
Revenue | $41,504 | $27,178 | $19,453 | $7,014 |
Gross Profit | 38,716 | 25,656 | 18,760 | 6,897 |
EBITDA | -12,304 | -25,494 | -24,918 | -34,515 |
EBIT | -12,741 | -26,035 | -24,900 | -35,110 |
Net Income | -13,822 | -27,342 | -28,786 | -36,274 |
Net Change In Cash | 41,504 | 27,178 | 19,453 | 7,014 |
Free Cash Flow | -17,994 | -29,704 | -28,028 | -38,226 |
Cash | 28,847 | 35,794 | 31,167 | 51,811 |
Basic Shares | 96,151 | 91,693 | 95,019 | 89,380 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
Revenue | $27,963 | $1,496 | $0 | $22,334 |
Gross Profit | 25,351 | -1,493 | -815 | 16,592 |
EBITDA | -136,083 | -93,723 | -84,567 | -31,607 |
EBIT | -137,849 | -95,216 | -85,382 | -33,297 |
Net Income | -160,276 | -137,464 | -77,329 | 7,028 |
Net Change In Cash | 27,963 | 1,496 | 0 | 22,334 |
Cost of Revenue | -20,118 | 61,228 | ||
Free Cash Flow | -132,868 | -71,020 | -77,336 | -48,832 |
Cash | 31,167 | 73,981 | 50,708 | 71,722 |
Basic Shares | 80,174 | 60,094 | 58,535 | 54,941 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-06-30 | -$0.14 |
2024-03-31 | -$0.30 |
2023-12-31 | -$0.29 |
2023-09-30 | -$0.41 |
